ADORA2A and cancer: In recent years, the discovery and translation of A2 AR antagonists from the bench to bedside for cancer immunotherapy have made significant progress, with some selective A2 AR antagonists entering clinical trials either alone or in combination with other immunotherapies (Figure 1)1,.20–23